Application Nr Approved Date Route Status External Links
ANDA074346 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Paser Is Indicated For The Treatment Of Tuberculosis In Combination With Other Active Agents. It Is Most Commonly Used In Patients With Multi-Drug Resistant Tb (Mdr-Tb) Or In Situations When Therapy With Isoniazid And Rifampin Is Not Possible Due To A Combination Of Resistance And/or Intolerance. When Paser Is Added To The Treatment Regimen In Patients Proven Or Suspected Drug Resistance, It Should Be Accompanied By At Least One And Preferably Two Other New Agents To Which The Patient's Organism Is Known Or Expected To Be Susceptible.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Aminosalicylic Acid

Comments